| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-04-20 | Takeda Pharmaceutical (Japan) Keio University School of Medicine (Japan) Niigata University (Japan) | disease-related RNA-binding proteins | collaboration R&D |
Cancer - Oncology - CNS diseases | Collaboration agreement | |
| 2015-04-20 | Roche (Switzerland) Curadev Pharma Private (India) | IDO1 and TDO inhibitors | development commercialisation |
Cancer - Oncology | Development agreement | |
| 2015-04-20 | Applied Genetic Technologies Corporation (USA - FL) 4D Molecular Therapeutics (4DMT) (USA - CA) | optimized AAV vectors | ophtalmological diseases | licensing collaboration |
Ophtalmological diseases | Licensing agreement |
| 2015-04-20 | Merck&Co (USA - NJ) TetraLogic Pharmaceuticals (USA - PA) | Keytruda® (pembrolizumab) and birinapant | relapsed or refractory solid tumors | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-04-20 | Horizon Discovery (UK) Thermo Fisher Scientific (USA - MA) | X-MAN human haploid and diploid isogenic cell line collection | supply commercialisation |
Technology - Services | Commercialisation agreement | |
| 2015-04-17 | NeuroVive Pharmaceutical (Sweden) Isomerase Therapeutics (UK) | cyclophilin-inhibiting molecules, NVP018/BC556, NVP014 | traumatic brain injury, ischemic stroke, heart attack, antiviral indications | R&D |
Cardiovascular diseases - Cerebrovascular diseases - Infectious diseases | R&D agreement |
| 2015-04-17 | CEVEC Pharmaceuticals (Germany) | nomination |
Technology - Services | Nomination | ||
| 2015-04-16 | Innate Pharma (France) Sanofi-Aventis Recherche & Développement (France) | new Antibody Drug Conjugates (ADC) | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2015-04-16 | MedImmune (USA - global biologics arm of AstraZeneca (UK) Immunocore (UK) | MEDI4736, tremelimumab, IMCgp100 | metastatic melanoma | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-04-15 | Iris Pharma (France) Oculos Clinical Research (USA - FL) | collaboration |
Ophtalmological diseases - Technology - Services | Collaboration agreement | ||
| 2015-04-15 | Celgene (USA - NJ) | nomination |
Cancer - Oncology - Inflammatory diseases | Nomination | ||
| 2015-04-14 | AstraZeneca (UK) The Lead Discovery Center (LDC) (Germany) | human diseases with high unmet medical need | R&D |
Cancer- Oncology - Neuroscience - Respiratory diseases - Inflammatory diseases - Cardiovascular diseases - Gastrointestinal diseases - Infectious diseases | R&D agreement | |
| 2015-04-14 | Abbott (USA - IL) Sekisui Diagnostics (Japan) | coagulation testing solutions including CP3000 coagulation instrument | collaboration |
Diagnostic - Hematological diseases - Genetic diseases - Cardiovascular diseases | Collaboration agreement | |
| 2015-04-14 | Thrombogenics (Belgium) VIB (Belgium) | Oncurious | Cancer - Oncology | Establishment of a new subsidiary in the EU | ||
| 2015-04-14 | Incyte (USA - DE) | establishment of a new subsidiary in the EU |
Cancer - Oncology - Rare diseases | Establishment of a new subsidiary in the EU | ||
| 2015-04-14 | Aptuit (UK) Axxam (Italy) | collaboration |
Technology - Services | Collaboration agreement | ||
| 2015-04-14 | 4SC (Germany) Menarini (Italy) | resminostat (oral pan-histone deacetylase (HDAC) inhibitor) | hepatocellular carcinoma and all oncological indications | development licensing |
Cancer - Oncology | Licensing agreement |
| 2015-04-14 | Thrombogenics (Belgium) VIB (Belgium) Oncurious (Belgium) | establishment of a new subsidiary in the EU | Cancer - Oncology | Establishment of a new subsidiary in the EU | ||
| 2015-04-13 | Molmed (Italy) San Raffaele Hospital (Italy) | CAR-CD44v6 (immune-gene therapy project against cancer developed using the Chimeric Antigen Receptor CD44v6) | solid tumours, hematological cancers | exercise of an option agreement | Cancer - Oncology | Exercise of an option agreement |
| 2015-04-13 | AstraZeneca (UK) PatientsLikeMe (USA - MA) | R&D collaboration |
Autoimmune diseases – Cancer - Oncology - Metabolic diseases - Respiratory diseases | Collaboration agreement |
